JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
about
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases.JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia.STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells
P2860
JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
JAK/STAT pathway inhibition ov ...... acute lymphoblastic leukemias.
@en
type
label
JAK/STAT pathway inhibition ov ...... acute lymphoblastic leukemias.
@en
prefLabel
JAK/STAT pathway inhibition ov ...... acute lymphoblastic leukemias.
@en
P2093
P2860
P356
P1433
P1476
JAK/STAT pathway inhibition ov ...... acute lymphoblastic leukemias
@en
P2093
C Delgado-Martin
J R Roderick
J V Nguyen
K A Shimano
M A Kelliher
P2860
P2888
P304
P356
10.1038/LEU.2017.136
P577
2017-05-09T00:00:00Z
P6179
1085375512